Physician profile
Jorge E Alvarez
NPI 1720396138
$8,222.73
in general payments reported to CMS, 2019-2025
13 companies · $2,273 in 2025
The $2,273 reported for 2025 was more than what 84% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2020: $504 · 2021: $968 · 2022: $1,066 · 2023: $616 · 2024: $2,588 · 2025: $2,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,594 · Travel and Lodging: $1,883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,594.30 |
| Travel and Lodging | $1,882.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $3,355.38 | 2020-2024 | Senza, Vyrsa V1 |
| Medtronic, INC. | $2,792.24 | 2022-2025 | Synchromedii, Inceptiv, Intellis Adaptivestim |
| Stryker Corporation | $899.84 | 2025 | Mild Device Kit, Optablate, Spinejack |
| Globus Medical, INC. | $525.04 | 2025 | Senza |
| Si-Bone, INC. | $233.97 | 2020-2023 | |
| Gilead Sciences, INC. | $121.88 | 2019 | |
| Boston Scientific Corporation | $78.78 | 2024-2025 | General - Therapies |
| Astrazeneca Pharmaceuticals Lp | $74.54 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $52.70 | 2024 | |
| Merck Sharp & Dohme LLC | $33.60 | 2020-2023 | Gardasil 9 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.85 | 2020 | |
| Avanos Medical | $14.64 | 2025 | Generator |
| Biodelivery Sciences International, INC. | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.